Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany
– Compassionate use enables treating physicians in Germany to request access to investigational TransCon PTH…
– Compassionate use enables treating physicians in Germany to request access to investigational TransCon PTH…
           NEWS RELEASE – REGULATED INFORMATION JUNE 5, 2023, 5:30 pm ET/ 23:30 CEST…
           NEWS RELEASE – REGULATED INFORMATION JUNE 5, 2023, 5:30 pm ET/ 23:30 CEST…
JUPITER-02 Final Overall Survival Analysis in Intent-To-Treat Population Presented at ASCO 2023 – Toripalimab plus…
JUPITER-02 Final Overall Survival Analysis in Intent-To-Treat Population Presented at ASCO 2023 – Toripalimab plus…
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leader…
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leader…
Company completes corporate reorganization focused on reducing operating costs while supporting key value creation drivers,…
Company completes corporate reorganization focused on reducing operating costs while supporting key value creation drivers,…
Preclinical data on UCART20x22, Cellectis’ first allogeneic dual CAR T-cell product candidate to treat B-NHL,…
Preclinical data on UCART20x22, Cellectis’ first allogeneic dual CAR T-cell product candidate to treat B-NHL,…
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage…
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage…
SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced…
SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced…
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), Humacyte, Inc. (Nasdaq:…
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), Humacyte, Inc. (Nasdaq:…
PETACH TIKVA, Israel, June 05, 2023 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”),…
PETACH TIKVA, Israel, June 05, 2023 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”),…
All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or…